Irinotecan care guided by tumor genes and gut bacteria
Part of Cancer, Digestive system clinical trials.
This study looks at whether a patient’s tumor genetic makeup and gut bacteria activity can predict how well irinotecan-based treatment works and what side effects they might have. It may help personalize treatment to improve survival and quality of life for people with metastatic or unresectable colon cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have metastatic or unresectable colorectal cancer and will receive irinotecan-based treatment (with or without an anti-EGFR medicine)
- You feel well enough for treatment (WHO performance status 0 to 2)
- Your blood counts and organ tests are within required ranges (bone marrow, liver, and kidney)
- You can sign the study consent form
- Your cancer is not MSI-high and you do not have deficient MMR proteins
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adjusting irinotecan treatment based on a person’s UGT1A1 gene test can improve outcomes for locally advanced rectal cancer. It focuses on people who are about to start (or continue) chemoradiation and do not have cancer spread to distant organs.
This trial tests a “microbiome health” product (a probiotic-type supplement) to improve how well irinotecan chemotherapy works for people with metastatic colon cancer. It aims to support gut health so treatment can be delivered effectively.
This study tests whether using a genetic test to guide medication doses works better than standard dosing for people with certain pancreas or colon cancers. It may help by tailoring treatment more precisely to your tumor’s genetic features.
This Phase I/II trial tests how well irinotecan combined with tislelizumab (an immunotherapy) treats advanced stomach or gastroesophageal junction adenocarcinoma. It mainly looks at safety and the best way to use this combination, and may help shrink tumors or slow disease growth.
This study is testing a combination of drugs for colorectal cancer that has spread and hasn't responded to first-line treatment. It aims to see if these drugs can help control the cancer and improve outcomes for people in your situation.
This trial tests a new type of chemotherapy (irinotecan liposomes) as a first treatment for metastatic colorectal cancer that has not been treated before. It focuses on patients with specific genetic changes (RAS or BRAF V600E mutation) or right-sided colon cancer, and looks at how well the drug works.
Hear when a new Colorectal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.